Clinical trial
Heart Outcomes Prevention Evaluation-3
NCT00468923 · Population Health Research Institute, Other · Completed
Key facts
| NCT number | NCT00468923 |
|---|---|
| Title | Heart Outcomes Prevention Evaluation-3 |
| Official title | Heart Outcomes Prevention Evaluation-3 |
| Acronym | HOPE-3 |
| Lead sponsor | Population Health Research Institute, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cardiovascular Disease, Stroke |
| Intervention type | Drug |
| Interventions | Candesartan/HCT, Rosuvastatin |
| Enrollment | 12,705 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2015 |
| Completion | Jan 1, 2016 |
| First posted | May 3, 2007 |
| Last update posted | Oct 25, 2017 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: